NCT02864225

Brief Summary

Background: Identification and measurement of fetal heart tracings throughout pregnancy and labor is crucial to the well-being of the fetus. Non reassuring fetal heart rate is one of the most common indications for operative vaginal delivery or cesarean section. Therefore, management of labor requires reliable and accurate information about fetal heart rate. In most normal spontaneous labors, fetal heart rate is characterized by the baseline heart rate (from 110 to 160 beats per minute), variability (beat to beat changes) and periodic changes (accelerations or decelerations). In each stage of labor the tracing may have different characteristics, with variable decelerations much more common at the end of the second stage of labor. Objective: To Show non inferiority of the EUM to the fetal doppler and scalp electrode by comparing the reliability and accuracy of the EUM versus fetal doppler compared to scalp electrode in the same patients.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Sep 2016

Typical duration for phase_3

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 8, 2016

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 11, 2016

Completed
21 days until next milestone

Study Start

First participant enrolled

September 1, 2016

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2019

Completed
Last Updated

August 15, 2016

Status Verified

August 1, 2016

Enrollment Period

3 years

First QC Date

August 8, 2016

Last Update Submit

August 11, 2016

Conditions

Outcome Measures

Primary Outcomes (4)

  • The difference between the fetal scalp electrode tracings and the EUM tracings of the fetal heart activity.

    Mean Positive Percent Agreement (PPA) for interpretable/un interpretable traces (between EUM, scalp electrode and fetal doppler).

    Up to 72 hours

  • Reliability

    Mean sensitivity for individual tracing identification (between EUM, scalp electrode and fetal doppler)

    Up to 72 hours

  • Reliability

    Mean Positive Predictive Value (PPV) for individual tracing identification (between EUM, scalp electrode and fetal doppler)

    Up to 72 hours

  • Reliability

    The mean False Positive Rate (FPR) for individual tracing identification (between EUM, scalp electrode and fetal Doppler)

    Up to 72 hours

Study Arms (1)

Scalp electrode, fetal doppler and EUM

EXPERIMENTAL

Once in labor, the parturient will be connected to the routine fetal doppler and EUM. When necessary according to clinical indications, the scalp electrode will be connected. Tracing will be recorded simultaneously from all three devices until delivery.

Device: Scalp electrode,Device: Fetal dopplerDevice: EUM

Interventions

the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler

Scalp electrode, fetal doppler and EUM

the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler

Scalp electrode, fetal doppler and EUM
EUMDEVICE

the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler

Scalp electrode, fetal doppler and EUM

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinical indication to insert a scalp electrode for fetal heart rate tracing.
  • Maternal age \>18 years
  • Reactive fetal heart rate monitoring and BPP 8/8 at enrollment
  • Singleton pregnancy
  • No fetal abnormality or chromosomal defect
  • Subjects are willing and able to comply with the requirements of the protocol.
  • Fully understand all elements of, and have signed and dated, the written informed consent form before initiation of protocol-specified procedures, when VAS \<3.

You may not qualify if:

  • Women who refused to sign the informed consent form.
  • Maternal age \< 18 years.
  • Multiple pregnancy
  • Woman with implanted electronic device of any kind
  • Woman with allergic to silver.
  • Irritated skin or open wound

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Yariv Yogev, professor

    Tel Aviv Medical Center

    STUDY CHAIR

Central Study Contacts

Yariv Yogev, professor

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NA
Masking
DOUBLE
Who Masked
CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 8, 2016

First Posted

August 11, 2016

Study Start

September 1, 2016

Primary Completion

September 1, 2019

Study Completion

September 1, 2019

Last Updated

August 15, 2016

Record last verified: 2016-08

Data Sharing

IPD Sharing
Will not share